$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Alzheimer's disease (AD) is a neurodegenerative disease that causes 60%-70% dementia around the world and costs much social resources1. It is well-known that accumulation of amyloid-β (Aβ) is a pathological hallmark in Alzheimer's disease. Amyloid precursor protein (APP) is an integral membrane protein that exists in many tissues. Aβ peptide, consisting of 36-42 amino acids2, is produced by the subsequent cleavage of β- and γ-secretase in APP3,4. Changes in APP cleavage and mutations in APP gene lead to overproduction of Aβ. Aβ molecules can aggregate to form oligomers or fibrils, which are believed to be neurotoxic5,6. In previous studies, the accumulation of Aβ was demonstrated to be correlated with neuronal death in AD7,8,9.
The 5×FAD (C57BL/6J) transgenic mice contain 3 mutations in APP, and 2 mutations in PSEN1. The accumulation of intracellular Aβ starts as early as 1.5 month of age. Extracellular accumulation of Aβ was found around 2 months, in the cortex and hippocampus. The accumulation increased rapidly with age10. The well-documented Aβ pathology makes it a good animal model for our protocol.
The goal of the described staining method is to visualize and quantify Aβ deposition in the brain of AD mice model. The procedure including transcardial paraformaldehyde perfusion, cryosectioning, immunofluorescent staining and quantification to detect Aβ accumulation in 5×FAD mice will be introduced. This protocol is a reliable and easy method to investigate Aβ pathology in AD mouse model.